---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-23-000030"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:28:00.608690+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Q1 net loss $20.9M; cash $103.4M; BDTX-1535 update H2 2023; BDTX-4933 IND cleared

## Summary
- Cash $103.4M as of March 31, down from $122.8M at year-end 2022; net loss $20.9M vs $25.5M in Q1 2022.
- Cash runway expected into Q3 2024.
- Phase 1 dose escalation of BDTX-1535 ongoing; clinical update on track for H2 2023; dose-expansion cohorts to open in 2023.
- FDA clearance for BDTX-4933 IND; first patient dosing expected in Q2 2023.
- Development candidate BDTX-4876 (FGFR 2/3 selective) nominated; company evaluating strategic alternatives for FGFR program.

## SEC filing metadata
- accession: 0001701541-23-000030
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/0001701541-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/bdtx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-23-000030
- JSON: https://secwatch.observer/filing/0001701541-23-000030.json
- Plain text: https://secwatch.observer/filing/0001701541-23-000030.txt

## Key facts
- Earnings Releases
  Black Diamond Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000170154123000030/0001701541-23-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.